secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2023-06-02T23:59:59+00:00
Accession:  0001213900-23-045834
Event type: regulatory
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics receives FDA guidance for briquilimab in CSU; IND filing and first patient dose expected in H2 2023
--------------------------------------------------------------------------------

- FDA provided guidance on the proposed program for briquilimab for chronic spontaneous urticaria (CSU).
- Company expects to file IND for briquilimab in CSU and dose first patient in H2 2023.
- Jasper will continue engagement with FDA toward IND submission and launch of CSU clinical trial.
- Updated corporate presentation posted on company website as of June 2, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023045834/0001213900-23-045834-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023045834/ea179684-8k_jasperthera.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-045834

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer